- AstraZeneca Plc AZN shared positive topline data from the CAPItello-291 Phase 3 trial of capivasertib in combination with Faslodex (fulvestrant) in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative locally advanced or metastatic breast cancer patients, following recurrence or progression on or after endocrine therapy.
- The capivasertib + Faslodex combo demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus Faslodex.
- The trial will continue to assess overall survival as a key secondary endpoint.
- Related: AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study.
- The safety profile of capivasertib plus Faslodex was similar to that observed in previous trials evaluating this combination.
- AstraZeneca also reported topline data from the SERENA-2 Phase 2 trial of camizestrant.
- The trial met the primary endpoint of demonstrating a statistically significant and clinically meaningful progression-free survival (PFS) benefit at 75mg and 150mg dose levels versus Faslodex 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.
- Tuesday, AstraZeneca reported a Phase 3 trial of Fasenra (benralizumab) that did not meet one of the two dual-primary endpoints in Eosinophilic esophagitis patients aged 12 years or older.
- Price Action: AZN shares are up 2.95% at $57.55 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CarePre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
